Trending Topic

Inflammation of the breast in women. Female breasts with signs of the disease. A low-poly construction of interconnected lines and points. Blue background.
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Mohammad Ammad Ud Din, Hania Liaqat, Ayesha Tayyab

The incidence rate of breast cancer (BC) is the highest in Pakistan among all Asian countries.1 In 2018 alone, 2.1 million cases were diagnosed, although the exact number is likely much higher due to poor reporting in rural areas and the lack of a formal national cancer registry.1,2 Over the last decade, multiple non-governmental organizations and large […]

Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 13th 2022

As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of first line enfortumab vedotin monotherapy or in combination with pembrolizumab in patients with la/mUC who have a high unmet need. Dr Rosenberg also highlights further clinical trial that are ongoing for the treatment of la/mUC.

The abstract entitled ‘Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)‘ Abstract LBA73, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What are the major unmet needs in the first-line treatment of locally advanced or metastatic urothelial cancer? (0:13)
  2. What is the rationale for investigating the combination of enfortumab vedotin and pembrolizumab in this treatment setting? (1:08)
  3. What were the design and eligibility criteria of Study EV-103? (2:08)
  4. What were the efficacy and safety findings of the study? (3:03)
  5. What further investigations of this combined therapy are planned? (4:05)

Disclosures: Jonathan Rosenberg is a consultant for Astellas, Seagen, Gilead, and Merck; receives grant/research support from Astellas, and Seagen; is on the advisory board for Astellas, Seagen, Gilead, and Merck; and receives honoraria/honorarium from Pfizer, and EMD-Serono.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more genitourinary cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup